Rocket Pharmaceuticals Inc RCKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial
-
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
-
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
-
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
-
Rocket Receives FDA Approval for Genetic Immunodeficiency Treatment
-
Rocket Pharmaceuticals Shares Surge after FDA Accepts Drug Application Resubmission
-
FDA Accepts Rocket Pharmaceuticals' BLA Resubmission for Rare Genetic Disorder Treatment
Trading Information
- Previous Close Price
- $2.63
- Day Range
- $2.58–2.75
- 52-Week Range
- $2.51–5.45
- Bid/Ask
- $2.56 / $2.63
- Shares Outstanding
- 109.77M
- Market Cap
- $284.32M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.05%
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 202
- Website
- https://www.rocketpharma.com
Valuation
|
Metric
|
RCKT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RCKT
|
|---|---|
Quick Ratio | 9.06 |
Current Ratio | 9.24 |
Interest Coverage | −7.11 |
Quick Ratio
RCKT
Profitability
|
Metric
|
RCKT
|
|---|---|
Return on Assets (Normalized) | −44.83% |
Return on Equity (Normalized) | −52.80% |
Return on Invested Capital (Normalized) | −50.31% |
Return on Assets
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|l&%VXZ | LOCK|XR!W | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Qd><MPn | LOCK|!Mj< | $76B | |||
| Moderna Inc
MRNA
| LOCK|#VL<$! | LOCK|&S! | $75B | |||
| argenx SE ADR
ARGX
| LOCK|T@%Mr< | LOCK|n>> | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#<Z!c& | LOCK|n$> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ZQmDq&m | LOCK|f#$B | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$RxGzLZ | LOCK|>W%Y@ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|HZL^SRM | LOCK|l&r | $24B | |||
| Incyte Corp
INCY
| LOCK|b!?FZ! | LOCK|xJ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KXy%h$# | LOCK|$@ | $15B |
United States